BioDuro-Sundia, a drug discovery and development services organization backed by Advent International, has entered into a definitive agreement to acquire a commercial oral solid dose manufacturing facility located in Irvine, California.

“This fully-audited and operational facility allows us to immediately support our clients who require larger scale commercial production,” said Kent Payne, who led the acquisition in his role as president, development and manufacturing US/EU at BioDuro-Sundia. “BioDuro-Sundia is a pioneer in enhancing bioavailability, with 25 years of experience applying stabilized amorphous solid dispersion technology to poorly soluble drug product candidates. Our clients have requested our support to provide commercial scale manufacturing to save time and maximize success, and it is a pleasure to take this next step with them.”